fbpx
QQQ
-2.47
341.35
-0.73%
DIA
-2.66
343.52
-0.78%
SPY
-3.01
418.34
-0.72%
TLT
+ 0.64
138.22
+ 0.46%
GLD
+ 0.60
165.30
+ 0.36%

Why Anavex Life Sciences Is Trading Lower Today

February 11, 2021 10:19 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Anavex Life Sciences's Stock Price And Volume Action

Anavex Life Sciences (NASDAQ:AVXL) is currently down 4.98% to a price of $13.41. The stock's current volume for the day is 718.10 thousand, which is approximately 11.45% of its previous 30-day average volume of 6.27 million.

Why It's Moving

Benzinga Pro's real-time breaking news service shows some insight into what is affecting shares: Anavex Life Sciences shares are trading lower after the company reported worse-than-expected Q1 EPS results.

Insights On Recent Price Action

The stock's 50-day moving average was $6.61 at the time this article was published. Over the past fifty-two weeks, the price has risen as high as $28.7 and fallen to a low of $2.2.

If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.

Posted-In:

Movers Trading Ideas

Related Articles

12 Health Care Stocks Moving In Tuesday's Intraday Session

  read more

61 Stocks Moving In Wednesday's Mid-Day Session

Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) shares jumped 193.3% to $11.00. Novo Integrated Sciences, on Tuesday, announced an uplist to The Nasdaq Capital Market. read more

48 Stocks Moving in Wednesday's Pre-Market Session

Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) rose 117.1% to $8.14 in pre-market trading. Novo Integrated Sciences, on Tuesday, announced an uplist to The Nasdaq Capital Market. read more

18 Stocks Moving In Tuesday's After-Hours Session

Gainers Upwork (NASDAQ: UPWK) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued Q1 & FY21 sales guidance above estimates. read more